Prof. MD Michael Dworzak

Publikovaná abstrakta

• Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients
• Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01
• Additional Prognostic Impact of Specific Sites of Extramedullary Leukemia in Pediatric AML with MLL-Rearrangements but Not in Core-Binding Factor (CBF) AML
• APPLICABILITY OF A REPRODUCIBLE FLOW CYTOMETRY SCORING SYSTEM IN THE DIAGNOSIS OF REFRACTORY CYTOPENIA OF CHILDHOOD
• Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood
• Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01
• Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study
• Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study
• Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML
• Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium
• Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes
• COMPARABLE OUTCOME OF IMMUNOSUPPRESSIVE THERAPY WITH RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) PLUS CYCLOSPORINE A (CSA) TO ONE WITH HORSE ATG PLUS CSA IN REFRACTORY CYTOPENIA IN CHILDHOOD
• Distribution and Outcome According to Cytogenetics in 502 Paediatric AML Patients Treated in Study AML-BFM 98
• Epigenetic Changes in CEBPα Gene and Xenotransplantation Model of B Cell Precursor Acute Lymphoblastic Leukemia Switching to Monocytoid Lineage During the Early Phase of the Treatment
• Excellent Outcome In Infants below One Year of Age with AML – Results of Studies AML-BFM -98 and -2004
• Exchange Transfusion and Leukapheresis in Pediatric AML Patients with High Risk of Early Death for Bleeding and Leukostasis
• High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia
• IER3 Expression in Childhood Myelodysplastic Syndrome
• IMPACT OF MRD STATUS PRIOR TO HSCT IN PEDIATRIC AML
• JMML Revisited: Role Und Outcome of Hematopoietic Stem Cell Transplantation in Subtypes of Juvenile Myelomonocytic Leukemia (JMML)
• Long-Term Continuing Second Complete Remission (CCR2) despite Allogeneic Stem Cell Transplantation in CR1: Results from the International Randomised Phase III Study Pediatric Relapsed AML 2001/01
• Molecular Aberrations in 107 Children with Myelodysplastic Syndrome (MDS)
• MRD Monitoring of Childhood ALL Using Hierarchical Clustering and Support Vector Machine Learning of Complex Multi-Parameter Flow Cytometry Data
• Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia
• Overexpression of the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated with a High Incidence of Relapses in Childhood Acute Myeloid Leukemia Treated with G-CSF
• Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Münster AML Study Group
• Preventive CNS Irradiation with 12 Gy Compared to 18 Gy: Results of Studies AML-BFM 98 and 2004
• Prognostic Significance of Early Treatment Response in Pediatric Relapsed Acute Myeloid Leukemia: Results from the International Study Relapsed AML 2001/01.
• Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01
• Refractory Cytopenia In Childhood (RCC) with Normal Karyotype Is Unlikely to Progress to Advanced MDS Under a Watch and Wait Strategy
• Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Report of the International Randomised Phase III Study Relapsed AML 2001/01
• Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium
• Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency
• Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity
• THE CLINICAL RELEVANCE OF MINOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONES IN REFRACTORY CYTOPENIA OF CHILDHOOD – A PROSPECTIVE STUDY BY EWOG-MDS
• The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC)
• Therapy-Related Myelodysplastic Syndrome Following Treatment for Childhood Acute Lymphoblastic Leukemia: Outcome of Patients Registered in the EWOG-MDS 98/06 Studies
• Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7
• Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol